Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10946) 10946
Newspaper Article (874) 874
Newsletter (354) 354
Book Chapter (124) 124
Magazine Article (118) 118
Dissertation (44) 44
Reference (42) 42
Book / eBook (37) 37
Transcript (14) 14
Conference Proceeding (13) 13
Government Document (9) 9
Book Review (8) 8
Web Resource (8) 8
Publication (5) 5
Streaming Video (5) 5
Video Recording (2) 2
Archival Material (1) 1
Journal / eJournal (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7820) 7820
thalidomide (6220) 6220
science & technology (6203) 6203
life sciences & biomedicine (6033) 6033
thalidomide - therapeutic use (3988) 3988
female (3868) 3868
male (3760) 3760
thalidomide - analogs & derivatives (2976) 2976
middle aged (2586) 2586
thalidomide - adverse effects (2377) 2377
aged (2234) 2234
thalidomide - administration & dosage (2219) 2219
multiple myeloma - drug therapy (2168) 2168
oncology (2087) 2087
multiple myeloma (2020) 2020
hematology (1994) 1994
adult (1982) 1982
biological and medical sciences (1853) 1853
medical sciences (1818) 1818
animals (1716) 1716
treatment outcome (1635) 1635
thalidomide - pharmacology (1463) 1463
antineoplastic combined chemotherapy protocols - therapeutic use (1371) 1371
lenalidomide (1211) 1211
bortezomib (1068) 1068
antineoplastic agents - therapeutic use (999) 999
care and treatment (938) 938
pharmacology. drug treatments (897) 897
research (876) 876
aged, 80 and over (852) 852
abridged index medicus (850) 850
pharmacology & pharmacy (794) 794
drug therapy (790) 790
aids/hiv (776) 776
dexamethasone - administration & dosage (771) 771
pregnancy (771) 771
angiogenesis inhibitors - therapeutic use (757) 757
immunosuppressive agents - therapeutic use (729) 729
cancer (689) 689
mice (629) 629
chemotherapy (609) 609
multiple myeloma - pathology (547) 547
dexamethasone (543) 543
hematologic and hematopoietic diseases (542) 542
recurrence (542) 542
dermatology (541) 541
abnormalities, drug-induced (517) 517
antineoplastic combined chemotherapy protocols - adverse effects (511) 511
medicine & public health (506) 506
prognosis (506) 506
antineoplastic agents (498) 498
health aspects (497) 497
analysis (494) 494
multiple myeloma - mortality (473) 473
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (470) 470
dose-response relationship, drug (469) 469
multiple myeloma - therapy (453) 453
disease-free survival (449) 449
rats (448) 448
general & internal medicine (440) 440
clinical trials as topic (435) 435
old medline (431) 431
medicine, general & internal (429) 429
drug therapy, combination (425) 425
immunopathology (417) 417
immunologic factors - therapeutic use (415) 415
retrospective studies (415) 415
toxicology (414) 414
immunodeficiencies. immunoglobulinopathies (409) 409
tumors (408) 408
immunoglobulinopathies (404) 404
remission induction (387) 387
risk factors (377) 377
follow-up studies (376) 376
immunology (373) 373
antineoplastic agents - adverse effects (370) 370
transplantation (364) 364
hematology, oncology and palliative medicine (361) 361
dosage and administration (357) 357
dexamethasone - therapeutic use (353) 353
antineoplastic combined chemotherapy protocols - administration & dosage (350) 350
survival analysis (349) 349
clinical trials (346) 346
time factors (345) 345
angiogenesis (343) 343
adolescent (336) 336
medical research (334) 334
boronic acids - administration & dosage (333) 333
pyrazines - administration & dosage (332) 332
survival rate (327) 327
boronic acids - therapeutic use (322) 322
disease progression (322) 322
pyrazines - therapeutic use (322) 322
child (321) 321
myelodysplastic syndromes - drug therapy (319) 319
multiple myeloma - complications (314) 314
multiple myeloma - diagnosis (312) 312
combined modality therapy (311) 311
patients (310) 310
thalidomide - toxicity (307) 307
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
Robarts - Stacks (9) 9
UTL at Downsview - May be requested (7) 7
Online Resources - Online (5) 5
OISE - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Trinity College (John W Graham) - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Law (Bora Laskin) - Stacks (2) 2
Media Commons - Audio Visual (2) 2
UofT at Mississauga - Stacks (2) 2
Criminology - Stacks (1) 1
East Asian (Cheng Yu Tung) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Law (Bora Laskin) - May be requested in 6-10 wks (1) 1
Music - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
OISE - May be requested in 6-10 wks (1) 1
St. Augustine's Seminary - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11164) 11164
German (443) 443
Japanese (283) 283
French (273) 273
Chinese (143) 143
Spanish (124) 124
Portuguese (107) 107
Italian (91) 91
Polish (61) 61
Czech (56) 56
Swedish (34) 34
Korean (26) 26
Dutch (25) 25
Russian (18) 18
Danish (14) 14
Hungarian (11) 11
Norwegian (8) 8
Finnish (7) 7
Hebrew (7) 7
Turkish (5) 5
Slovak (4) 4
Ukrainian (4) 4
Romanian (3) 3
Persian (2) 2
Serbian (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
by Attal, Michel and Lauwers-Cances, Valerie and Marit, Gerald and Caillot, Denis and Moreau, Philippe and Facon, Thierry and Stoppa, Anne Marie and Hulin, Cyrille and Benboubker, Lofti and Garderet, Laurent and Decaux, Olivier and Leyvraz, Serge and Vekemans, Marie-Christiane and Voillat, Laurent and Michallet, Mauricette and Pegourie, Brigitte and Dumontet, Charles and Roussel, Murielle and Leleu, Xavier and Mathiot, Claire and Payen, Catherine and Avet-Loiseau, Hervé and Harousseau, Jean-Luc and IFM Investigators
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunopathology | General aspects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Bone marrow, stem cells transplantation. Graft versus host reaction | Transfusions. Complications. Transfusion reactions. Cell and gene therapy | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Young Adult | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Chemotherapy | Consolidation | Transplants & implants | Clinical trials | Stem cell transplantation | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Abridged Index Medicus | Antineoplastic Agents | Life Sciences | Neoplasms, Second Primary | Thalidomide | Multiple Myeloma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
by McCarthy, Philip L and Holstein, Sarah A and Petrucci, Maria Teresa and Richardson, Paul G and Hulin, Cyrille and Tosi, Patrizia and Bringhen, Sara and Musto, Pellegrino and Anderson, Kenneth C and Caillot, Denis and Gay, Francesca and Moreau, Philippe and Marit, Gerald and Jung, Sin-Ho and Yu, Zhinuan and Winograd, Benjamin and Knight, Robert D and Palumbo, Antonio and Attal, Michel
Journal of clinical oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3279 - 3289
Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Transplantation, Autologous | Young Adult | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - therapy | Time Factors | Adult | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Stem Cell Transplantation - mortality | Angiogenesis Inhibitors - adverse effects | Thalidomide - adverse effects | Drug Administration Schedule | Lenalidomide | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Thalidomide - administration & dosage | Disease Progression | Randomized Controlled Trials as Topic | Disease-Free Survival | Aged | Stem Cell Transplantation - adverse effects | Index Medicus | Life Sciences | Angiogenesis Inhibitors/administration & dosage | Multiple Myeloma/therapy | Thalidomide/analogs & derivatives | Cancer | Rapid Communications | Myeloma | Clinical Trials | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
by Schafer, P.H and Parton, A and Capone, L and Cedzik, D and Brady, H and Evans, J.F and Man, H.-W and Muller, G.W and Stirling, D.I and Chopra, R
Cellular signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
by Morschhauser, Franck and Fowler, Nathan H and Feugier, Pierre and Bouabdallah, Kamal and Bouabdallah, Reda and Tilly, Hervé and Palomba, M. Lia and Fruchart, Christophe and Libby, Edward N and Casasnovas, Rene-Olivier and Flinn, Ian W and Haioun, Corinne and Maisonneuve, Hervé and Ysebaert, Loic and Bartlett, Nancy L and Brice, Pauline and Ribrag, Vincent and Daguindau, Nicolas and Le Gouill, Steven and Pica, Gian M and Martin Garcia-Sancho, Alejandro and López-Guillermo, Armando and Larouche, Jean-François and Ando, Kiyoshi and Gomes da Silva, Maria and André, Marc and Zachée, Pierre and Sehn, Laurie H and Tobinai, Kensei and Cartron, Guillaume and Liu, David and Wang, Jianming and Xerri, Luc and Salles, Gilles A and RELEVANCE Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 10, pp. 934 - 947
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thalidomide - adverse effects | Skin Diseases - chemically induced | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, Follicular - mortality | Male | Survival Rate | Thalidomide - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Neutropenia - chemically induced | Rituximab - adverse effects | Chemotherapy | Usage | Lymphomas | Drug therapy | Cancer | Fees & charges | Lymphocytes B | Immunomodulation | Immunotherapy | Advisors | Rituximab | Clinical medicine | Patients | Lymphoma | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Separation of [alpha]-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXR[alpha]-selective antagonists
by Motoshima, Kazunori and Noguchi-Yachide, Tomomi and Sugita, Kazuyuki and Hashimoto, Yuichi and Ishikawa, Minoru
Bioorganic & medicinal chemistry, ISSN 0968-0896, 07/2009, Volume 17, Issue 14
Thalidomide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
by Tehranchi, Ramin and Woll, Petter S and Anderson, Kristina and Buza-Vidas, Natalija and Mizukami, Takuo and Mead, Adam J and Åstrand-Grundström, Ingbritt and Strömbeck, Bodil and Horvat, Andrea and Ferry, Helen and Dhanda, Rakesh Singh and Hast, Robert and Rydén, Tobias and Vyas, Paresh and Göhring, Gudrun and Schlegelberger, Brigitte and Johansson, Bertil and Hellström-Lindberg, Eva and List, Alan and Nilsson, Lars and Jacobsen, Sten Eirik W
The New England journal of medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 11, pp. 1025 - 1037
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | ADP-ribosyl Cyclase 1 - analysis | Antigens, CD34 - analysis | Neoplastic Stem Cells - drug effects | Humans | Middle Aged | Neoplastic Stem Cells - immunology | Male | Antineoplastic Agents - therapeutic use | Thalidomide - pharmacology | Thalidomide - analogs & derivatives | Aged, 80 and over | Female | Antineoplastic Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Chromosomes, Human, Pair 5 - genetics | Chromosome Deletion | Gene Expression | Remission Induction | Drug Resistance - genetics | Phenotype | Aged | Myelodysplastic Syndromes - genetics | Thalidomide - therapeutic use | Myelodysplastic Syndromes - pathology | Thy-1 Antigens - analysis | Stem cells | Physiological aspects | Chromosome deletion | Genetic aspects | Diagnosis | Research | Health aspects | Myelodysplastic syndromes | Bone marrow | Patients | Cancer | Index Medicus | Abridged Index Medicus | Thalidomide: therapeutic use | Myelodysplastic Syndromes: pathology | Neoplastic Stem Cells: drug effects | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinsk genetik | Medical Genetics | Antineoplastic Agents: pharmacology | Thalidomide: analogs & derivatives | Myelodysplastic Syndromes: genetics | CD34: analysis | Chromosomes | Pair 5: genetics | Human | Antigens | Basic Medicine | Thy-1: analysis | Cell and Molecular Biology | Drug Resistance: genetics | CD38: analysis | Thalidomide: pharmacology | Neoplastic Stem Cells: immunology | Medicinska och farmaceutiska grundvetenskaper | Antineoplastic Agents: therapeutic use | Myelodysplastic Syndromes: drug therapy | Cell- och molekylärbiologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
by Chamberlain, Philip P and Lopez-Girona, Antonia and Miller, Karen and Carmel, Gilles and Pagarigan, Barbra and Chie-Leon, Barbara and Rychak, Emily and Corral, Laura G and Ren, Yan J and Wang, Maria and Riley, Mariko and Delker, Silvia L and Ito, Takumi and Ando, Hideki and Mori, Tomoyuki and Hirano, Yoshinori and Handa, Hiroshi and Hakoshima, Toshio and Daniel, Thomas O and Cathers, Brian E and Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Nature structural & molecular biology, ISSN 1545-9993, 09/2014, Volume 21, Issue 9, pp. 803 - 809
Biochemistry & Molecular Biology | Biophysics | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Protein Structure, Tertiary | Amino Acid Sequence | Lenalidomide | Humans | Thalidomide - chemistry | Angiogenesis Inhibitors - pharmacology | Molecular Sequence Data | Crystallography, X-Ray | Thalidomide - pharmacology | DNA-Binding Proteins - chemistry | Peptide Hydrolases - chemistry | DNA-Binding Proteins - metabolism | Thalidomide - analogs & derivatives | Sequence Alignment | Animals | Protein Binding | Protein Conformation | Mice | Molecular Docking Simulation | Angiogenesis Inhibitors - chemistry | Peptide Hydrolases - metabolism | Research | Structure | Thalidomide | Patient outcomes | Crystals | Proteins | Cancer therapies | Pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
by Attal, Michel and Lauwers-Cances, Valerie and Hulin, Cyrille and Leleu, Xavier and Caillot, Denis and Escoffre, Martine and Arnulf, Bertrand and Macro, Margaret and Belhadj, Karim and Garderet, Laurent and Roussel, Murielle and Payen, Catherine and Mathiot, Claire and Fermand, Jean P and Meuleman, Nathalie and Rollet, Sandrine and Maglio, Michelle E and Zeytoonjian, Andrea A and Weller, Edie A and Munshi, Nikhil and Anderson, Kenneth C and Richardson, Paul G and Facon, Thierry and Avet-Loiseau, Hervé and Harousseau, Jean-Luc and Moreau, Philippe and IFM 2009 Study
The New England journal of medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights